Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)
An Open Label, Randomized Study of Nilotinib vs. Standard Imatinib (400/600 mg QD) Comparing the Kinetics of Complete Molecular Response for CML-CP Patients With Evidence of Persistent Leukemia by RQ-PCR.
研究概览
研究类型
注册 (实际的)
阶段
- 第三阶段
联系人和位置
学习地点
-
-
British Columbia
-
Vancouver、British Columbia、加拿大、V5Z 1M9
- Novartis Investigative Site
-
-
Ontario
-
Hamilton、Ontario、加拿大、L8H 4J9
- Novartis Investigative Site
-
Toronto、Ontario、加拿大、M5G 2M9
- Novartis Investigative Site
-
-
Quebec
-
Montreal、Quebec、加拿大、H1T 2M4
- Novartis Investigative Site
-
Québec、Quebec、加拿大、G1J 1Z4
- Novartis Investigative Site
-
-
-
-
MG
-
Belo Horizonte、MG、巴西、30130-100
- Novartis Investigative Site
-
-
PR
-
Curitiba、PR、巴西、80060-900
- Novartis Investigative Site
-
-
RJ
-
Rio de Janeiro、RJ、巴西、21941-913
- Novartis Investigative Site
-
-
SP
-
Campinas、SP、巴西、13083-970
- Novartis Investigative Site
-
Sao Paulo、SP、巴西、05403-000
- Novartis Investigative Site
-
-
-
-
-
Bordeaux、法国、33076
- Novartis Investigative Site
-
Creteil、法国、94010
- Novartis Investigative Site
-
Lyon cedex 04、法国、69317
- Novartis Investigative Site
-
Paris、法国、75010
- Novartis Investigative Site
-
Vandoeuvre les Nancy、法国、54511
- Novartis Investigative Site
-
-
-
-
New South Wales
-
St. Leonards、New South Wales、澳大利亚、2065
- Novartis Investigative Site
-
Westmead、New South Wales、澳大利亚、2145
- Novartis Investigative Site
-
-
Queensland
-
Herston、Queensland、澳大利亚、4029
- Novartis Investigative Site
-
South Brisbane、Queensland、澳大利亚、4101
- Novartis Investigative Site
-
Woolloongabba、Queensland、澳大利亚、4102
- Novartis Investigative Site
-
-
South Australia
-
Adelaide、South Australia、澳大利亚、5000
- Novartis Investigative Site
-
-
Victoria
-
Parkville、Victoria、澳大利亚、3050
- Novartis Investigative Site
-
Prahran、Victoria、澳大利亚、3181
- Novartis Investigative Site
-
-
Western Australia
-
Nedlands、Western Australia、澳大利亚、6009
- Novartis Investigative Site
-
-
-
-
-
Madrid、西班牙、28006
- Novartis Investigative Site
-
Madrid、西班牙、28007
- Novartis Investigative Site
-
-
Andalucia
-
Malaga、Andalucia、西班牙、29010
- Novartis Investigative Site
-
-
Cataluña
-
Barcelona、Cataluña、西班牙、08036
- Novartis Investigative Site
-
-
Navarra
-
Pamplona、Navarra、西班牙、31008
- Novartis Investigative Site
-
-
-
-
Buenos Aires
-
Caba、Buenos Aires、阿根廷、C1221ADH
- Novartis Investigative Site
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Diagnosis of chronic myeloid leukemia associated with BCR-ABL quantifiable by RQ-PCR Documented CCyR by bone marrow or BCR-ABL<1% IS in the past 12 months Persistent disease demonstrated by two PCR positive tests 3 months apart both during the past 6 months.
Treatment with imatinib for at least 2 years with 400 mg or 600 mg and a stable dose No other current or planned anti-leukemia therapies
Exclusion Criteria:
Patient has evidence of rising PCR (a confirmed >1 log increase in previous 6 months) Patient has received another investigational agent within last 6 months or tyrosine kinase inhibitors (TKIs) other than imatinib Prior allogeneic stem cell transplantation
Impaired cardiac function including any one of the following:
Inability to monitor the QT interval on electrocardiogram (ECG) Long QT syndrome or a known family history of long QT syndrome. Clinically significant resting brachycardia (<50 beats per minute) QTc > 450 msec on baseline ECG (using the QTcF formula). If QTcF >450 msec and electrolytes are not within normal ranges, electrolytes should be corrected and then the patient re-screened for QTc Myocardial infarction within 12 months prior to starting study Other clinically significant uncontrolled heart disease (e.g. unstable angina, congestive heart failure or uncontrolled hypertension) History of or presence of clinically significant ventricular or atrial tachyarrhythmias Administration of cytokine therapy (e.g. G-CSF, GM-CSF or SCF) within 4 weeks prior to study entry
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Nilotinib
Participants received Nilotinib 400 mg orally twice daily (bid) for 48 months.
|
Supplied in 200 mg capsules
|
|
有源比较器:Imatinib
Participants received Imatinib 400 mg or 600 mg once daily (qd) (based on the participant's dose prior to randomization) for 48 months.
|
Supplied in 100 mg and 400 mg capsules
其他名称:
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Confirmed Best Cumulative Complete Molecular Response (CMR)
大体时间:12 months
|
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the first 12 months of treatment after the randomization date.
Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders.
Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders.
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by real-time quantitative polymerase chain reaction (RQ-PCR) where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
12 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Rate of Confirmed Best Cumulative CMR
大体时间:24 months, 36 month, 48 months
|
The rate of confirmed best cumulative CMR was defined as the number of participants who had confirmed CMR during the 24, 36 and 48 months post treatment after the randomization date.
Participants who achieved confirmed best cumulative CMR during the first 12 months were considered responders.
Participants who dropped out early or who did not provide sufficient data for any reason were considered to be non-responders.
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
24 months, 36 month, 48 months
|
|
Number of Cross-over Participants With CMR
大体时间:24 months, 36 months, 48 months
|
The definition of CMR is undetectable BCR-ABL (fusion gene formed between bcr gene from chromosome 22 and abl gene from chromosome 9) where BCR-ABL ratio in % international scale (IS) ≤ 0.00001 by RQ-PCR where there was no detectable BCR-ABL and 1) the test had a sensitivity of at least 4.5 logs below the standardized baseline; 2) RQ-PCR negativity was confirmed on the next RQ-PCR sample (usually 3 months later); and 3) the date of confirmed CMR was the date of the first of two negative results with sensitivity >4.5 logs.
|
24 months, 36 months, 48 months
|
|
Progression Free Survival (PFS)
大体时间:48 months
|
PFS was defined as the time from the date of randomization to the date of the earliest documented progression-defining event as follows: transformation to blast crisis or accelerated phase disease, or death from any cause.
|
48 months
|
|
Event-free Survival
大体时间:48 months
|
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest.
|
48 months
|
|
Overall Survival
大体时间:48 months
|
Overall survival was defined as the time from the date of randomization to the date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.
|
48 months
|
合作者和调查者
出版物和有用的链接
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.